Compass Therapeutics : 2024 Proxy Supplemental

UNITED STATES


SECURITIES AND EXCHANGE COMMISSION


Washington, D.C. 20549


SCHEDULE 14A


Proxy...

Related Keywords

United States ,Washington ,Delaware ,Massachusetts ,Boston ,Neil Lerner ,Vered Bisker Leib ,Thomas Schuetz ,Ellen Chiniara ,Carl Gordon ,Company Board Of Directors The ,Board Of Directors The Company ,Securities Exchange ,Compass Therapeutics Inc ,Commission File Number ,Exchange Act ,Company The Separation Agreement ,Company On ,Nasdaq ,Consulting Services ,Statement Pursuant ,Commission Only ,Material Pursuant ,Specified In Its Charter ,Filing Proxy Statement ,Filing Fee ,Exchange Act Rules ,Securities Exchange Act ,Principal Executive Offices ,Zip Code ,Securities Act ,Certain Officers ,Compensatory Arrangements ,Chief Executive Officer ,Principal Executive Officer ,Principal Financial ,Accounting Officer ,Compass Therapeutics ,Separation Agreement ,Consulting Agreement ,Consulting Period ,Consulting End Date ,Consulting End ,Vice Chair ,Principal Accounting Officer ,Current Report ,Proxy Statement ,Chief Executive ,Page Interactive Data File ,Benefits Upon Termination ,Good Reason Outside ,Employment Agreement ,Employment Separation Date ,Senior Consultant ,Equity Documents ,Separation Date ,Base Salary ,Such Severance Amount ,Consolidated Omnibus Budget Reconciliation Act ,Severance Amount ,Option Exercise Period ,Exercise Period Extension ,Severance Benefits ,Exercise Period ,Age Discrimination ,Employment Act ,Massachusetts Wage Act ,Accrued Obligations ,Press Release ,Employment Separation ,Agreement Related Information ,